[ad_1]
Dublin, June 16, 2021 /PRNewswire/– “Global pneumococcal vaccine market (2021-2026) by vaccine type, product, sector, distribution channel, geography, competition analysis, and COVID-19 impact and Ansoff analysis” Report has been added to ResearchAndMarkets.com provide.
Global pneumococcal vaccine market estimate USD 8.4 billion Expected to reach in 2021 $11.8 billion By 2026, it will grow at a compound annual growth rate of 7%.
Factors such as the rising prevalence of pneumococcal disease in the population and the introduction of new vaccines have supported the market growth. The government’s increasing awareness program on pneumococcal disease has also contributed to market growth. In addition, the development, testing and release of new vaccines with higher serotype coverage will bring growth opportunities to this market and help increase coverage.
However, the long time required to introduce vaccines and the additional costs in the vaccine development process hinder the growth of this market.
Market segments covered
In terms of vaccines, conjugate vaccines are expected to be the fastest growing part during the forecast period. They are considered stronger than polysaccharides and therefore more popular, leading to high demand. It also covers a wide range of age groups, because it can vaccinate babies from 6 weeks old to 5 years old and people over 50 years old, reducing the asymptomatic transmission of bacteria, thereby generating significant herd immunity.
By product type, Prevnar-13 is expected to account for the fastest growing part during the forecast period, as it is recommended by the World Health Organization as an effective pneumonia vaccine, and therefore has become a 13-valent PCV vaccine widely used worldwide. It is also used as a basic vaccine for people over 50 years of age.
By sector, the private sector is considered to be the largest sector contributing to growth during the forecast period. This is mainly due to the large number of private hospitals and clinics. Compared with non-governmental organizations or government aid centers, the cost of selling vaccines in private hospitals and/or clinics is relatively high, leading to high growth in activities.
Through distribution channels, with the presence of UNICEF, the Global Alliance for Vaccines and Immunization and the World Health Organization, NGOs are expected to achieve the fastest growth during the forecast period. They are the main promoters of this vaccine, driving demand in this market segment by distributing the vaccine from the source (manufacturer) to the destination (geographical location).
By geography, North America It is expected to occupy the largest market share. The factors that promote the growth of this market are the mature healthcare system, heavy investment in research and development, and government initiatives. For example, the United States calls on the Healthy People 2020 Goal Initiative to increase the coverage of pneumococcal vaccination to 60% among high-risk adults aged 18-64 and 90% among 65-year-olds. In addition, with the increase in the number of pneumonia cases, people’s awareness of immunization continues to increase, which further promotes market growth.
Company Profile
Some of the companies involved in this report include Pfizer, GlaxoSmithKline, Merck, Sanofi Pasteur, Nuron Biotech Inc., CSL Ltd., Biomed Pvt. Co., Ltd., China Biotechnology Group, and India Serum Research Corp.Limited company
Competition quadrant
The report includes a competition quadrant, which is a proprietary tool that analyzes and evaluates a company’s position based on its industry position score and market performance score. The tool uses various factors to divide players into four categories. Some of the factors considered for analysis are financial performance, growth strategies, innovation scores, new product launches, investments, market share growth in the past 3 years, etc.
lion: It represents a company that has a firm foothold in the market, has the highest market share, and has invested heavily in technology and new products.
Bulls: Medium-sized companies compete with their USPs, and growing companies have a solid market share.
rabbit: Small companies are growing rapidly, constantly improving their products in the market.
tortoise: Companies with slow growth, long history, stable performance or negative growth.
Why buy this report?
- The report provides a comprehensive assessment of the global pneumococcal vaccine market.
- The report includes in-depth qualitative analysis, verifiable data from real sources, and forecasts of market size. These predictions are calculated using proven research methods.
- The report was compiled through extensive primary and secondary research. The main research is done through interviews, surveys and observations of well-known figures in the industry.
- The report includes in-depth market analysis using the Porter 5 force model and the Ansoff matrix. The report also describes the impact of Covid-19 on the market.
- The report also includes a competitive analysis using the Competitive Quadrant (analyst’s proprietary competitive positioning tool).
Highlights of the report:
- Complete analysis of the market including the parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current and projected market size based on value and transaction volume
- Market shares and strategies of major players
- Suggestions for the company to strengthen its market foothold
Key topics covered:
1 Report description
2 Research methods
3 Executive summary
4 Market overview
4.1 Introduction
4.2 Market dynamics
4.2.1 Driver
4.2.2 Restrictions
4.2.3 Opportunity
4.2.4 Challenge
4.3 Trend
5 Market analysis
5.1 Porter’s five forces analysis
5.2 Impact of COVID-19
5.3 Ansoff matrix analysis
6 Global pneumococcal vaccine market, by vaccine type
6.1 Introduction
6.2 Pneumococcal Conjugate Vaccine (PCV)
6.3 Pneumococcal polysaccharide vaccine (PPSV/PPV)
7 Global pneumococcal vaccine market, by product type
7.1 Introduction
7.2 Foreword 13
7.3 Synflorix
7.4 Pneumovax 23
8 Global pneumococcal vaccine market, by sector
8.1 Introduction
8.2 Public sector
8.3 Private sector
9 Global pneumococcal vaccine market, by distribution channel
9.1 Introduction
9.2 Dealer Partner Company
9.3 Non-Governmental Organization (NGO)
9.4 Government agencies
10 Global pneumococcal vaccine market, divided by region
10.1 Introduction
10.2 North America
10.2.1 United States
10.2.2 Canada
10.2.3 Mexico
10.3 South America
10.3.1 Brazil
10.3.2 Argentina
10.4 Europe
10.4.1 United Kingdom
10.4.2 France
10.4.3 Germany
10.4.4 Italy
10.4.5 The rest Europe
10.5 Asia Pacific
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4 Australia
10.5.5 The rest of the Asia-Pacific region
10.6 middle East with Africa
11 Competitive landscape
11.1 The competition quadrant
11.2 Market Share Analysis
11.3 Competition Scenario
11.3.1 M&A
11.3.2 Agreements, cooperation and partnerships
11.3.3 New product release and enhancement
11.3.4 Investment and financing
12 Company profile
12.1 GlaxoSmithKline
12.2 LG Chemical Co., Ltd.
12.3 Merck
12.4 Wanneng Biotechnology Co., Ltd.
12.5 Pfizer
12.6 Pnuvax Company
12.7 Soldiers listed in the Indian Serum Study.Limited company
12.8 Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biological Technology Co., Ltd.)
12.9 SK Biological Sciences
12.10 Warwick Biotechnology Co., Ltd.
12.11 Nurem Biotech Company,
12.12 CSL Co., Ltd.
12.13 Biomedical Pvt. Ltd.
12.14 Sanofi Pasteur
12.15 China National Biotechnology Group
12.16 Astellas Pharmaceuticals
12.17 AstraZeneca PLC
12.18 Emerging Biological Solutions Company
12.19 Johnson & Johnson
13 Appendix
For more information about this report, please visit https://www.researchandmarkets.com/r/byecs
Media Contact:
Research and market
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST office hours, please call +1-917-300-0470
US/Canada toll free number +1-800-526-8630
GMT office hours call +353-1-416-8900
US Fax: 646-607-1904
Fax (outside the United States): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/worldwide-pneumococcal-vaccine-industry-to-2026—development-of-protein-based-combination-pneumococcal-vaccines-presents-opportunities-301313989.html
Source research and market
[ad_2]
Source link
